Gland, Switzerland
DBS System, a medtech company based in the Swiss Health Valley, specializes in advanced technology for collecting and preparing blood samples in a less invasive, easier, cheaper, and safer manner. The company's patent-pending microfluidic technology enables plasma/serum extraction and volume control in a standardized, reliable format, significantly enhancing the potential of DBS samples in bioanalysis. The innovative HemaXis platform combines laboratory testing and health monitoring, aiming to democratize blood collection and support "big data" initiatives for personalized medicine. Founded in 2010, the company received a significant Fr.2.50M Series A investment on 04 May 2017 from 3wVentures, Verve Ventures, and the Nest Collective Foundation.
DBS System's mission to "make blood samples travel - not people" aligns with the growing demand for efficient and personalized healthcare solutions. With its focus on precision, industry standards, and the potential to revolutionize blood collection, the company holds promise for disrupting the traditional methods of sample collection and analysis in the healthcare industry. As the company continues to develop its technology and expand its reach, it presents an intriguing opportunity for venture capitalists looking to support innovative solutions in the health care sector.
In conclusion, DBS System's cutting-edge technology, strategic positioning in the Swiss Health Valley, and recent successful Series A investment make it a compelling prospect for potential investors seeking opportunities in the evolving health care industry.
